NCT03921671 2024-05-29
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
Clinical Trials
96 trialsNCT04641078 2024-02-28
DART
University Hospital, Ghent
Phase 2 Unknown
NCT04617457 2024-01-12
HOLIPANC
University of Cologne
Phase 2 Unknown
NCT05237349 2024-01-05
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT02624128 2023-11-13
V-CHANCE
National Cancer Institute, Naples
Phase 2 Unknown
NCT05520814 2023-09-21
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT05904457 2023-06-15
BRISK
Asan Medical Center
Phase 2 Unknown
NCT05885399 2023-06-02
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03567720 2023-06-01
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
OncoSec Medical Incorporated
Phase 2 Unknown
NCT03803436 2023-03-16
COLT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT05077280 2022-12-06
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
California Pacific Medical Center Research Institute
Phase 2 Unknown
NCT03487016 2022-09-08
FOOTPATH
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT05530200 2022-09-07
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT05438706 2022-06-30
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
Fudan University
Phase 2 Unknown
NCT04116775 2022-06-23
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
Portland VA Medical Center
Phase 2 Unknown
NCT02499367 2022-03-22
TONIC
The Netherlands Cancer Institute
Phase 2 Unknown
NCT04835402 2022-03-09
EPIC-1
Aalborg University Hospital
Phase 2 Unknown
NCT04808466 2022-02-21
WUHIPEC01
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT02595320 2021-12-20
X7-7
University of Kansas Medical Center
Phase 2 Unknown
NCT02689167 2021-11-29
SURF
Centre Hospitalier Universitaire de Besancon
Phase 2 Unknown
NCT05136768 2021-11-29
LM-HNSCC
ChineseAMS
Phase 2 Unknown
NCT03219775 2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2 Unknown
NCT05095636 2021-10-27
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Fudan University
Phase 2 Unknown
NCT02795650 2021-02-26
AVATAR
Hospital Universitario de Fuenlabrada
Phase 2 Unknown
NCT04761744 2021-02-21
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Korean Cancer Study Group
Phase 2 Unknown
NCT04698213 2021-01-06
TIDE-A
Consorzio Oncotech
Phase 2 Unknown
NCT03013101 2020-09-30
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Unknown
NCT03113266 2020-09-30
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Unknown
NCT03129412 2020-09-17
Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02226289 2020-09-02
BATTLE
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT02162914 2020-07-31
REACHIN
Erasme University Hospital
Phase 2 Unknown
NCT04385654 2020-05-13
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
West China Hospital
Phase 2 Unknown
NCT00276783 2020-03-05
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
Northwestern University
Phase 2 Unknown
NCT02690480 2020-02-05
FLIPPER
Spanish Breast Cancer Research Group
Phase 2 Unknown
NCT03913182 2020-02-05
Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
Shanghai Chest Hospital
Phase 2 Unknown
NCT03022734 2020-01-13
Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis
Yonsei University
Phase 2 Unknown
NCT04180007 2019-11-27
APT-01
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT03592199 2019-09-04
SuAx
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT01823003 2019-08-07
sbrtlungfff
Institut Català d'Oncologia
Phase 2 Unknown
NCT03864575 2019-07-12
NICE-COMBO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT02007148 2019-02-27
MICADO
International Group of Endovascular Oncology
Phase 2 Unknown
NCT03299452 2019-02-15
Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
Haining Health-Coming Biotech Co., Ltd.
Phase 2 Unknown
NCT02913859 2018-10-11
Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer
University Hospital Sestre Milosrdnice
Phase 2 Unknown
NCT03585673 2018-07-17
DOSE
Dong-A University Hospital
Phase 2 Unknown
NCT03588533 2018-07-17
HERZUMA-GC
Dong-A University Hospital
Phase 2 Unknown
NCT03560856 2018-06-18
PALPETBIO
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03502343 2018-04-18
Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer
Yonsei University
Phase 2 Unknown
NCT02311205 2017-12-18
COTSOM
Asan Medical Center
Phase 2 Unknown
NCT03147963 2017-05-10
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown